Description
STIVARGA is indicated for patients with a type of liver cancer called hepatocellular carcinoma in people who have been previously treated with sorafenib.
STIVARGA is a once-daily, oral prescription anticancer medicine approved by the FDA for people with mCRC, GIST, and HCC
INDICATIONS
STIVARGA (regorafenib) is a prescription medicine used to treat people with:
- colon or rectal cancer that has spread to other parts of the body and for which they have received previous treatment with certain chemotherapy medicines
- a rare stomach, bowel, or esophagus cancer called GIST (gastrointestinal stromal tumor) that cannot be treated with surgery or that has spread to other parts of the body and for which they have received previous treatment with certain medicines
- a type of liver cancer called hepatocellular carcinoma (HCC) in people who have been previously treated with sorafenib
It is not known if STIVARGA is safe and effective in children less than 18 years of age.
STIVARGA for CRC
STIVARGA is a once-daily, prescription anticancer medicine for patients who have received previous treatment with certain chemotherapy medicines to treat colon cancer (CRC) that has now spread to other parts of the body. STIVARGA can be taken at home and has been shown to help some patients live longer and prevent the cancer from progressing vs placebo.
STIVARGA for GIST
STIVARGA is a once-daily, prescription anticancer medicine that you can take at home and has been shown to help previously treated patients with gastrointestinal stromal tumor (GIST), which is a rare stomach, bowel, or esophagus cancer) to prevent the cancer from progressing. STIVARGA is for patients who cannot be treated with surgery or who have had cancer spread to other parts of the body and have received previous treatment with certain medicines
STIVARGA for HCC
STIVARGA is a once-daily, prescription anticancer medicine that you can take at home and has been shown to help patients previously treated with sorafenib live longer vs placebo, and prevent the cancer from progressing.
Approved:
The European Medicines Agency decided that Stivarga’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Download for details: STIVARGA
